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Abstract
Introduction: In gene expression experiments, hormone receptor (HR)-positive/human epidermal growth factor-2
(HER2)-positive tumors generally cluster within the luminal B subset; whereas HR-negative/HER2-positive tumors
reside in the HER2-enriched subset. We investigated whether the clinical behavior of HER2-positive tumors differs
by HR status.
Methods: We evaluated 3,394 patients who presented to National Comprehensive Cancer Network (NCCN) centers
with stage I to III HER2-positive breast cancer between 2000 and 2007. Tumors were grouped as HR-positive/HER2-
positive (HR+/HER2+) or HR-negative/HER2-positive (HR-/HER2+). Chi-square, logistic regression and Cox hazard
proportional regression were used to compare groups.
Results: Median follow-up was four years. Patients with HR-/HER2+ tumors (n = 1,379, 41% of total) were more
likely than those with HR+/HER-2+ disease (n = 2,015, 59% of total) to present with high histologic grade and
higher stages (P <0.001). Recurrences were recorded for 458 patients. HR-/HER2+ patients were less likely to
experience first recurrence in bone (univariate Odds Ratio (OR) = 0.53, 95% Confidence Interval (CI): 0.34 to 0.82,
P = 0.005) and more likely to recur in brain (univariate OR = 1.75, 95% CI: 1.05 to 2.93, P = 0.033). A lower risk of
recurrence in bone persisted after adjusting for age, stage and adjuvant trastuzumab therapy (OR = 0.53, 95% CI:
0.34 to 0.83, P = 0.005) and when first and subsequent sites of recurrence were both considered (multivariable
OR = 0.55, 95% CI: 0.37 to 0.80, P = 0.002).
As compared with patients with HR+/HER2+ disease, those with HR-/HER2+ disease had significantly increased
hazard of early, but not late, death (hazard ratio of death zero to two years after diagnosis = 1.92, 95% CI: 1.28 to
2.86, P = 0.002, hazard ratio of death two to five years after diagnosis = 1.55, 95% CI: 1.19 to 2.00, P = 0.001; hazard
ratio of death more than five years after diagnosis = 0.81, 95% CI: 0.55 to 1.19, P = 0.285, adjusting for age, race/
ethnicity, stage at diagnosis, grade and year of diagnosis).
Conclusions: Presenting features, patterns of recurrence and survival of HER2-positive breast cancer differed by HR
status. These differences should be further explored and integrated in the design of clinical trials.
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Introduction
Breast cancer is a heterogeneous disease, with substantial
genotypic and phenotypic diversity [1]. In gene expression
experiments, hormone receptor (HR) segregates tumors
before human epidermal growth factor 2 (HER2), suggest-
ing that HR status is the most important discriminator of
breast cancers. HR-positive is used to categorize breast
tumors in two major groups [1-3]: luminal A and luminal
B and HR-negative cancers include normal-like, HER2
enriched, basal and claudin-low subtypes [1,4-6]. Most of
the clinically HR-positive/HER2-positive (HR+/HER2+)
cancers tend to fall in the luminal B subtype, and most of
HR-negative/HER2-positive (HR-/HER2+) in the HER2
enriched subtype [7].
In clinical practice, patients with HR+/HER2+ tumors
routinely receive endocrine therapy. In some cases, the
threshold to consider chemotherapy and trastuzumab is
slightly higher than in patients with HR-/HER2+ tumors.
However, despite their molecular differences, HER2-posi-
tive tumors are often treated as a single entity, and trials
for HER2-positive disease typically include patients irre-
spective of HR status.
Increasingly, some differences in clinical outcomes, tim-
ing and patterns of dissemination within HER2-positive
disease according to HR have been reported [8-16]. How-
ever, adjuvant trials have frequently reported only the sites
of initial, but not subsequent, recurrence. Because of selec-
tion bias, studies of patients with metastatic disease are
not ideal for examining sites and timing of recurrence
associated with HR status in HER-2-positive disease
overall.
Since 1997, the National Comprehensive Cancer Net-
work (NCCN) Breast Cancer Outcomes Database has col-
lected data on women with newly diagnosed breast cancer
presenting to many of its member institutions across the
United States [17]. The large size of the cohort allows for
investigation of the impact of HR within HER2-positive
breast tumors, with potentially less bias than relying on
clinical trial data alone. We aimed to describe clinico-
pathological features, patterns of recurrence and clinical




Data are collected prospectively within the NCCN Data-
base mainly through review of medical records and institu-
tional tumor registries. Vital status and cause of death are
determined from medical records and confirmed using the
Social Security Death Index and the National Death Index
(NDI). Data are subjected to rigorous quality assurance
[18]. Institutional review boards from each center
approved the study. At centers where a signed informed
consent was required, only patients who provided consent
were included; elsewhere, the institutional review boards
grant a waiver of signed informed consent.
Patient selection
Patients were included in the analytic group if they pre-
sented with newly diagnosed, stage I to III, unilateral,
HER2-positive invasive breast cancer between January
2000 and December 2007, at 1 of 13 NCCN institutions:
Arthur G. James Cancer Hospital at Ohio State University
(Columbus, OH), City of Hope Comprehensive Cancer
Center (Duarte, CA), Dana-Farber Cancer Institute (Bos-
ton, MA), Duke University Medical Center (Durham, NC),
Fox Chase Cancer Center (Philadelphia, PA), H. Lee Mof-
fitt Cancer Center (Tampa, FL), Massachusetts General
Hospital (Boston, MA), Robert H. Lurie Comprehensive
Cancer Center of Northwestern University (Chicago, IL),
Roswell Park Cancer Institute (Buffalo, NY), Seattle Can-
cer Care Alliance (Seattle, WA), Siteman Cancer Center
(St. Louis, MO), The University of Texas M.D. Anderson
Cancer Center (Houston, TX), and University of Michigan
Comprehensive Cancer Center (Ann Arbor, MI). Of 3,395
eligible women, one had unknown HR status and was
excluded, leaving an analysis sample size of 3,394 patients.
Definition of HER2 subgroups
Tumors were grouped as HR-positive (estrogen receptor
(ER) and/or progesterone receptor (PR) positive)/HER2-
positive and HR-negative (ER and PR negative)/HER2-
positive, using pathologic information of the primary
tumor, as specified below.
Covariates of interest
Tumor characteristics
The database contains information on tumor size, nodal
status, grade, lymphovascular invasion (LVI), extensive
intraductal component (EIC), ER and PR status and HER2
status, as abstracted from pathology reports. Stage is
assigned according to the version of the American Joint
Committee on Cancer (AJCC) Staging Manual applicable
at the time of diagnosis. Tumor grade was categorized as
high (according to histologic grade, or, if not available, by
nuclear grade) or low-intermediate. For HER2 classifica-
tion, we used the fluorescence in situ hybridization (FISH)
result, if available. If only immunohistochemistry (IHC)
was available, 3+, “high positive” or “positive NOS” were
considered HER2-positive; while 2+, 1+, 0 or “negative”
were considered HER2-negative; 6% (n = 199) of patients
were “positive NOS”.
Patient characteristics
We used the following variables collected by chart
review: age at diagnosis, height and weight, method of
detection, sites of breast cancer recurrence, treatment
types and vital status. Body mass index (BMI) was calcu-
lated as weight(kg)/height(m)2 [1] and grouped according
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to categories defined by the National Heart, Lung and
Blood Institute as follows: <18.5 kg/m2 underweight; 18.5
to 24.9 normal; 25.0 to 29.9 overweight, and >30.0 obese.
Data on race/ethnicity, menopausal status and comor-
bidity score [19] came from patient surveys conducted
at initial presentation to the NCCN center. Patients
were considered postmenopausal if they were amenor-
rheic for more than six months prior to breast cancer
diagnosis, were taking hormone replacement therapy or
were at least 50 years of age without a documented




The clinicopathological features at the time of diagnosis
were tabulated by HR status and proportions were com-
pared between groups using chi-square tests. This was
performed for the overall cohort, and separately among
the subgroup of patients with documented recurrence.
Treatment variables also were tabulated at the time of
diagnosis and at the time of recurrence by HR status.
Sites of recurrence analysis
Sites of recurrence were tabulated by HR status in the
overall cohort, the subgroup of patients with early recur-
rence (defined as those diagnosed within five years of
initial diagnosis) and the subgroup of patients with late
recurrence (those diagnosed more than five years from
initial diagnosis). In the overall cohort, univariate fol-
lowed by multivariable logistic regression estimated the
risk of sites of recurrence (first and first plus subsequent
sites of recurrence). In the multivariable analysis, the esti-
mated risk of recurrence was adjusted by age at diagnosis
(<50, ≥50 years), stage at diagnosis (I, II, III), and adju-
vant trastuzumab (yes/no).
Agreement between primary and metastatic samples
analysis
Among patients with data from paired primary and meta-
static samples, agreement (yes or no) between ER, PR and
HER2 status was tabulated and inter-rater agreement
between ER, PR and HER2 in primary and recurrent sam-
ples was calculated (simple kappa (K) coefficients and
asymptotic standard error (ASE) were used).
Survival outcomes analysis
Follow-up for overall survival (OS) and breast cancer spe-
cific survival (BCSS) were defined as time in years from
diagnosis to date of death or last known vital status.
BCSS was determined by identifying cause of death due
to breast cancer based on the International Statistical
Classification of Disease codes. Cox proportional hazards
regression was used to calculate OS while adjusting for
covariates. Hazard ratios and their associated 95% confi-
dence interval (95% CI) of any death, and breast cancer-
specific death, are presented by HR status (using HR
positive as the reference group) and also grouped by HR
and adjuvant trastuzumab use. In the latter analysis, the
following groups were assembled: patients with HR-posi-
tive tumors who received adjuvant trastuzumab, patients
with HR-negative tumors who received adjuvant trastu-
zumab, patients with HR-positive tumors who did not
receive adjuvant trastuzumab, and patients with HR-
negative tumors who did not receive trastuzumab; the
first group was used as the reference group. Cox models
were adjusted for age at diagnosis (<50, ≥50 years), race
(Caucasian, African American, Other, Unknown), stage
at diagnosis (I, II, III), grade (Low/Intermediate, High),
and year of diagnosis (2000 to 2007). The risk of death
since diagnosis by HR was found to be non-proportional
and, therefore, HR was modeled as a time dependent
covariate. The cut-points of zero to two, two to five and
more than five years were selected a priori because it is
well known that, after diagnosis, the peak hazard of
recurrence in breast cancer occurs within the first two
years, decreases consistently in the interval of two to five
years, and decreases even more slowly beyond five years
[20]. All P-values presented are two-sided; a P-value less
than 0.05 was considered significant. All statistical ana-
lyses were performed using SAS 9.2 (SAS Institute Inc.,
Cary, NC, USA).
Results
Description of the study cohort
A total of 3,394 patients were included in this analysis.
Subgroup distribution was: HR+/HER2+ 59% (n = 2,015)
and HR-/HER2+ 41% (n = 1,379). Median follow-up time
was four years (range: 0 to 11 years). The mean age at
diagnosis was 52 years. The majority (79%) of patients
were Caucasian.
Clinicopathological characteristics and patterns of care
Compared to patients with HR+/HER2+ tumors, patients
with HR-/HER2+ tumors were more likely to present
with higher T stage (T3 to T4, 17% vs. 10%, P <0.001),
nodal involvement (52% vs. 45%, P <0.001), higher AJCC
stage (Stage III, 28% vs. 18%, P <0.001) and higher histo-
logic grade (81% vs. 60%, P <0.001). Approximately one-
third of women in both groups presented on the basis of
a screening mammogram. Only small absolute differ-
ences were observed in the distribution of HR+/HER2+
vs. HR-/HER2+ tumors by race or menopausal status
(Table 1).
Most (79%) patients received neoadjuvant or adjuvant
chemotherapy. Overall, 44% of patients received neoadju-
vant or adjuvant trastuzumab. As expected, receipt of
adjuvant or neoadjuvant trastuzumab increased over time
(8% of patients diagnosed in 2000, 66% of patients diag-
nosed in 2005, and 77% of patients diagnosed in 2007,
data not shown) (Additional file 1, Table S1).
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Table 1 Patient demographics and clinicopathological characteristics for Stage I, II, III patients with HER2-positive
breast cancer










Age, mean (se), y 52.48 (0.21) 52.41 (0.29) 52.59 (0.32)
Age category, N, (%) <.001
0 to <50 1,514 (45) 931 (46) 583 (42)
50 to <70 1,547 (46) 865 (43) 682 (49)
70+ 333 (10) 219 (11) 114 (8)
Race/Ethnicity, N, (%) 0.030
African-American 259 (8) 135 (7) 124 (9)
Caucasian 2,693 (79) 1,627 (81) 1,066 (77)
Hispanic 262 (8) 155 (8) 107 (8)
Asian Pacific Island 126 (4) 64 (3) 62 (5)
American Indian 10 (<1) 4 (<1) 6 (<1)
Other 16 (<1) 10 (1) 6 (<1)
Unknown 28 (1) 20 (1) 8 (1)
Menopausal Status, N, (%) 0.001
Premenopausal 1,569 (46) 978 (49) 591 (43)
Postmenopausal 1,825 (54) 1,037 (51) 788 (57)
Body Mass Index kg/m2, N, (%) 0.512
<18.5 kg/m2 (Underweight) 52 (2) 34 (2) 18 (1)
18.5 to <25 kg/m2 (Normal) 1,263 (37) 750 (37) 513 (37)
25 to <30 kg/m2 (Obese) 913 (27) 554 (27) 359 (26)
>30 kg/m2 (Severely Obese) 884 (26) 506 (25) 378 (27)
Missing/unknown 282 (8) 171 (8) 111 (8)
Co-morbidity score, N, (%) 0.958
0 2,713 (80) 1,609 (80) 1,104 (80)
1 452 (13) 271 (13) 181 (13)
2+ 229 (7) 135 (7) 94 (7)
Method of detection, N, (%) <.001
Abnormal screening mammogram 1,209 (36) 755 (37) 454 (33)
Symptom 2,012 (59) 1,175 (58) 837 (61)
Other 147 (4) 67 (3) 80 (6)
Unknown 26 (1) 18 (1) 8 (1)
T stage, category, N, (%) <.001
T1 1,753 (52) 1,103 (55) 650 (47)
T2 1,150 (34) 691 (34) 459 (33)
T3 244 (7) 129 (6) 115 (8)
T4 197 (6) 73 (4) 124 (9)
Unknown 50 (1) 19 (1) 31 (2)
Nodal status, N, (%) <.001
Positive 1,623 (48) 907 (45) 716 (52)
Negative 1,757 (52) 1,101 (55) 656 (48)
Unknown 14 (<1) 7 (<1) 7 (<1)
AJCC stage, N, (%) <.001
I 1,187 (35) 772 (38) 415 (30)
II 1,467 (43) 887 (44) 580 (42)
III 740 (22) 356 (18) 384 (28)
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Recurrence was documented in 458 women. Of these,
45% had HR+/HER2+ tumors and 55% had HR-/HER2+
tumors. A total of 32 patients experienced recurrences
beyond five years (66% HR-positive and 34% HR-negative).
At first recurrence, most (68%) of patients received che-
motherapy; 86% of these patients received concurrent
Table 1 Patient demographics and clinicopathological characteristics for Stage I, II, III patients with HER2-positive
breast cancer (Continued)
Histologic grade, N, (%) <.001
Low/Intermediate 907 (27) 719 (36) 188 (14)
High 2,324 (68) 1,211 (60) 1,113 (81)
Unknown 163 (5) 85 (4) 78 (6)
Histology, N, (%) <.001
Invasive ductal 3,101 (91) 1,772 (88) 1,329 (97)
Invasive lobular 105 (3) 89 (4) 16 (1)
Mixed ductal and lobular 139 (4) 120 (6) 19 (1)
Other 49 (1) 34 (2) 15 (1)
LVI, N, (%) 0.630
Presence 1,164 (34) 678 (34) 486 (35)
Absence 2,113 (62) 1,267 (63) 846 (61)
Unknown 117 (3) 70 (3) 47 (3)
EIC, N, (%) 0.536
Presence 606 (18) 353 (18) 253 (18)
Absence 2,788 (82) 1,662 (82) 1,126 (82)








Disease free interval median (range), y 1.95 (7.69) 2.24 (7.69) 1.70 (7.08)
Age, mean (se), y 50.95 (0.60) 50.39 (0.94) 51.41 (0.78)
Race/Ethnicity, N, (%) 0.644
African-American 51 (11) 21 (10) 30 (12)
Caucasian 358 (78) 166 (80) 192 (77)
Hispanic 31 (7) 12 (6) 19 (8)
Asian Pacific Island 12 (3) 6 (3) 6 (2)
American Indian 1 (<1) 1 (<1) 0 (0)
Other 4 (1) 1 (<1) 3 (1)
Unknown 1 (<1) 1 (<1) 0 (0)
Menopausal status at time of diagnosis of index cancer, N, (%) 0.207
Premenopausal 223 (49) 108 (52) 115 (46)
Postmenopausal 235 (51) 100 (48) 135 (54)
Co-morbidity score at time of diagnosis of index cancer, N, (%) 0.437
0 371 (81) 166 (80) 205 (82)
1 57 (12) 25 (12) 32 (13)
2+ 30 (7) 17 (8) 13 (5)
AJCC stage at time of diagnosis of index cancer, N, (%) 0.437
I 77 (17) 36 (17) 41 (16)
II 188 (41) 91 (44) 97 (39)
III 193 (42) 81 (39) 112 (45)
Histologic grade at time of diagnosis of index cancer, N, (%) 0.016
Low/Intermediate 65 (14) 40 (19) 25 (10)
High 379 (83) 163 (79) 216 (86)
Unknown 14 (3) 5 (2) 9 (4)
Note: AJCC, American Joint Committee on Cancer Staging; EIC, extensive intraductal component; HR, Hormone receptor; LVI, Lymphovascular invasion; se,
standard error; y, year
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HER2-based therapy, either trastuzumab or lapatinib
(Additional file 1, Table S1).
Patterns of recurrence
Type of first recurrence by HR
At first recurrence, the risks of local vs. distant recur-
rence by HR status appeared similar (Table 2; Addi-
tional file 2, Table S2). Brain involvement was present
in 20% of patients with documented recurrence of HR-/
HER2+ tumors and in 13% of patients with documented
recurrence of HR+/HER2+ tumors (Additional file 3,
Table S3). Bone disease was present in 28% of patients
with HR+/HER2+ breast cancer and in 17% of patients
with HR-/HER2+ tumors (Additional file 3, Table S3).
By univariate analysis, patients with HR-negative tumors
were more likely to experience brain recurrence (OR =
1.75, 95% CI: 1.05 to 2.93, P = 0.033), and less likely to
have bone recurrence (OR = 0.53, 95% CI: 0.34 to 0.82,
P = 0.005). After multivariable adjustment, the differ-
ence in risk of bone recurrence persisted (OR = 0.53,
95% CI: 0.34 to 0.83, P = 0.005); however, the difference
in risk of brain recurrence was only borderline signifi-
cant (OR = 1.63, 95% CI: 0.95 to 2.81, P = 0.079). No
differences in risk of lung or liver as the first site of
recurrence by HR were observed (Table 2). The type of
recurrence among patients with documented recurrence
in the early and late recurring subgroup is represented
in Additional files 4, 5, 6, 7, Tables S4-7. Overall the
pattern of recurrence in the early recurring subgroup is
similar to the overall cohort. In the late recurring sub-
group, bone disease was present in 19% of patients with
HR+/HER2+ tumors and in 9% of patients with HR-/
HER2+ tumors. Brain involvement was present in 24%
with HR+/HER2+ tumors and in 18% of patients with
HR-/HER2+ tumors. Lung disease was present in 38%
of patients with late recurrence versus 15% in the early
recurring subgroup.
Type of first and subsequent recurrence by HR
Combining first and subsequent sites of recurrence, brain
involvement was present in 40% of patients with docu-
mented recurrence of HR-/HER2+ breast cancer and in
33% of patients with documented recurrence of HR+/
HER2+ tumors. Thirty-four percent of patients with HR-/
HER2+ tumors had bone recurrence compared to 49% of
patients with HR+/HER2+ tumors. Lung involvement
was present in 40% of patients with HR-/HER2+ tumors
and in 31% of patients with HR+/HER2+ tumors. As
such, combining first and subsequent sites of recurrence,
patients with HR-negative tumors were slightly more
likely to experience lung involvement (OR = 1.48, 95%
CI: 1.00 to 2.18, P = 0.05) and less likely to recur in bone
(OR = 0.54, 95% CI: 0.37 to 0.78, p= 0.001). In multivari-
able analysis, this pattern persisted for bone recurrence
(OR = 0.55, 95% CI: 0.37 to 0.80, P = 0.002) and became
even less significant for lung recurrence (OR = 1.45, 95%
CI: 0.98 to 2.15, P = 0.061). No association of HR with
brain or liver disease was found. In the multivariable
model, young age (OR = 1.66, 95% CI: 1.11 to 2.47, P =
0.014), higher stage at presentation (Stage III vs. Stage I:
OR = 2.05, 95% CI: 1.12 to 3.75, P = 0.020) and adjuvant
trastuzumab use (OR = 1.61, 95% CI: 1.06 to 2.46,
P = 0.025) were significantly associated with brain invol-
vement when compared to other sites of recurrence.
Adjuvant trastuzumab was associated with a decrease
in the risk of liver recurrence vs. other sites of recurrence
(OR = 0.63, 95% CI: 0.41 to 0.96, P = 0.033). No
other differences in recurrence sites with adjuvant trastu-
zumab were observed (Table 3; Additional files 8, 9,
Tables S8, S9).
Agreement between primary and metastatic samples
Among patients with available data (n = 126 for evalua-
tion of ER status, n = 123 for evaluation of PR status, and
n = 121 for evaluation of HER2 status), ER status chan-
ged (positive to negative, or vice versa) in 22% of patients;
PR status changed (positive to negative, or vice versa) in
29% of patients; HER2 status changed from positive to
negative in 17% of patients. Because the cohort was
defined as HER2-positive patients, we were unable to
describe the number of patients whose HER2 converted
from negative to positive. There was a 49% rate of any
discordance within the available data (Table 4).












1.06 (0.71, 1.59) 0.772 1.15 (0.75, 1.76) 0.531
Brain vs. Other 1.75 (1.05, 2.93) 0.033 1.63 (0.95, 2.81) 0.079
Bone vs. Other 0.53 (0.34, 0.82) 0.005 0.53 (0.34, 0.83) 0.005
Lung vs. Other 1.24 (0.76, 2.03) 0.393 1.27 (0.77, 2.09) 0.353
Liver vs. Other 1.38 (0.86, 2.22) 0.188 1.44 (0.89, 2.35) 0.139
Note: HR, Hormone receptor. Adjusting by age at diagnosis, stage and adjuvant trastuzumab.
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Survival outcomes
Among 3,394 patients, death was recorded in 13% of
patients (N = 457), and breast-cancer specific death in
10% of patients (N = 337). The risk of death was not
proportional over time for HR status and time depen-
dent covariates yielded patients with HR-negative
tumors having significantly increased hazard in the first
five years (hazard ratio of death zero to two years =
1.92, 95% CI: 1.28 to 2.86, P = 0.002; hazard ratio of
death two to five years = 1.55, 95% CI: 1.19 to 2.00, P =
0.001; hazard ratio of death more than five years = 0.81,
95% CI: 0.55 to 1.19, P = 0.285) (Figure 1). Similar
results were seen for BCSS (data not shown).
HR-negative status and lack of adjuvant trastuzumab
were associated with increased hazards. The hazards for
patients with HR-negative tumors who did not receive
adjuvant trastuzumab (median survival for HR-negative
tumors that did not receive trastuzumab: 4.48 years)
were amplified when compared to patients with HR-
positive tumors who received trastuzumab (median sur-
vival for HR-positive tumors that received trastuzumab:
8.43 years) (Figure 2).
Discussion
In this large cohort of patients with Stage I to III HER2-
positive breast cancer, we found significant associations
between HR status and presenting features, patterns of
recurrence and survival outcomes. As compared with
patients with HR-positive tumors, those with HR-nega-
tive tumors were less likely to recur in bone. In addi-
tion, 20% of patients with HR-negative tumors recurred
first in the brain compared with 13% of HR-positive
patients. Moreover, HR-negative patients experienced
more deaths in the first five years, compared with HR-
positive patients, but no statistically significant differ-
ences in hazards of death beyond Year 5 were found.
Our studies confirm other studies regarding the impact
of HR status on sites of recurrence in HER2 disease
[13,21-23]. Non-overlapping organ-specific signatures of
recurrence in breast cancer have previously been recog-
nized. Moreover, molecular subtypes have been asso-
ciated with preferential sites of relapse. For instance, in
the luminal subtypes (HR-positive subtypes) bone relapse
is frequent and brain relapse is usually less common
[24-29]. In our study, this pattern of recurrence was also
found in the HR+/HER2+ tumors. Our results suggest
that HR status remains a major driver of clinical pheno-
type, even among HER2-positive patients.
Due to the small number of patients with late recur-
rence, we cannot draw definitive conclusions about
recurrence patterns by HR in patients with early versus
late recurrences and, therefore, our results are only










0.71 (0.44,1.15) 0.162 0.74 (0.44, 1.23) 0.246
Brain vs. Other 1.37 (0.93, 2.02) 0.107 1.31 (0.88, 1.95) 0.191
Bone vs. Other 0.54 (0.37, 0.78) 0.001 0.55 (0.37, 0.80) 0.002
Lung vs. Other 1.48 (1.00, 2.18) 0.050 1.45 (0.98, 2.15) 0.061
Liver vs. Other 1.01 (0.69, 1.48) 0.954 1.06 (0.72, 1.56) 0.764
Note: HR, Hormone receptor. Adjusting by age at diagnosis, stage and adjuvant trastuzumab.








Total (N) 126 123 121
Agreement,
N (%)
Yes 98 (78) 0.55 (0.074) 86 (70) 0.31 (0.083) 101 (83) 0.003
(0.019)
No 28 (22) 37 (29) 20 (17)
+ to - 18 (14) 30 (24) 20 (17)
- to + 10 (8) 7 (6) N/A
Note: + to - , change from positive to negative marker; - to +, change from negative to positive marker; ER, estrogen receptor; HER2, Human epidermal growth
factor 2; HR, Hormone receptor; PR, progesterone receptor. *Data were available in a limited number of samples due to unknown information in the metastatic
setting.
Vaz-Luis et al. Breast Cancer Research 2012, 14:R129
http://breast-cancer-research.com/content/14/5/R129
Page 7 of 14
hypothesis-generating. A total of 38% of patients in the
late recurring subgroup relapsed in the lung, with no
apparent difference according to HR status; whereas 15%
of patients in the early recurring group had recurrence in
the lung (including 13% of HR-positive patients and 18%
of HR-negative patients). In the early recurrence sub-
group, HR-negative patients seemed to be more likely to
experience brain relapse as the first site of recurrence
compared with HR-positive patients. This difference
appears to disappear in the late recurring subgroup. It
would be of potential interest to explore other datasets to
determine if these findings are consistent across studies.
Overall, the incidence of brain metastasis in HER2-
positive disease has been described as 25 to 55% [30-33].
Some, but not all, studies have reported differences in the
frequency of brain metastases according to HR status.
Kennecke et al. reported a frequency of 29% in HR-/
HER2+ disease compared with 15% in HR+/HER2+ dis-
ease [13]. Brufsky et al. reported frequencies of 44% and
31%, respectively, among patients with either HR-/HER2+
disease, compared with HR+/HER2+ disease [33].
In the adjuvant trastuzumab trials in HER2-positive
disease, the overall risk of brain recurrence was small
(NSABP B-31/NCCTG N9831 trials: 1%, HERA trial:
Number at risk
HR-positive 2,015 1,924 1,391 756 308 100
HR-negative 1,379 1,280 910 475 256 77
Hazard Ratio (95% CI) P-val
HR-negative vs. HR-positive
0-2 years 1.92 (1.28, 2.86) 0.002
2-5 years 1.55 (1.19, 2.00) 0.001
>5 years 0.81 (0.55, 1.19) 0.285
Figure 1 Overall survival since time of diagnosis by HR status. Note: HR, Hormone receptor. Adjusted by age, race/ethnicity, stage at
diagnosis, grade and year of diagnosis.
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1%); however, the brain represented an important pro-
portion of the sites for first recurrences (NSABP B-31/
NCCTG N9831 trial: 18%, HERA trial: 10%) [34,35].
Similarly, in our study, 20% of first recurrences in
patients with HR-negative tumors and 13% of first
recurrences in HR-positive patients occurred in the
brain. Combining first and subsequent sites of recur-
rence, 40% of HR-negative patients and 33% of HR-posi-
tive patients had brain involvement. The most striking
differences were found in the incidence of the brain as
the site of first recurrence, with differences between the
groups attenuating over time and after adjusting to clin-
icopathological factors. Similar to previous findings,
young age, higher presenting stage and adjuvant trastu-
zumab use were associated with a higher likelihood of
brain recurrence [36].
It is notable that previous efforts to define a gene signa-
ture predictive of central nervous system (CNS) relapse
among patients with HER2-positive disease did not suc-
ceed in identifying a predictor of the presence or absence
of CNS relapse, but were successful in distinguishing
between those patients with early versus late brain
relapse [37]. Our data support the hypothesis that biolo-
gic factors predisposing to early brain relapse are prob-
ably not the same as those predisposing to later CNS
involvement. Moreover, within the subgroup of patients
Number at risk  
HR-positive TRZ     837                    811                   478                   143                    43                    8 
HR-negative TRZ     665                    625                   390                   136         
HR-positive No TRZ  1,178                 1,115                   926                   617                   266                 93 
HR-negative No TRZ     714                    656                   521                   349                   215                 68 
  
  Hazard Ratio (95% CI)    P-value   Hazard Ratio (95% CI)   P-value   Hazard Ratio (95% CI)   P-value   
    HR-negative                                     HR-positive                                     HR-negative                         
TRZ                                                   No TRZ                                             No TRZ 
0-2 years      2.84 (1.33, 6.06)                0.007        3.42 (1.59, 7.36)            0.002         6.01 (2.83,12.81)         <.001 
2-5 years      2.58 (1.59, 4.20)               <.001         3.07 (1.87, 5.03)            <.001         3.97 (2.40, 6.57)          <.001 
>5 years       0.41 (0.16, 1.05)               0.064         0.98 (0.56, 1.72)            0.952          0.93 (0.52, 1.67)         0.806 
Figure 2 Overall survival since time of diagnosis by HR status and receipt adjuvant trastuzumab. Note: Reference group are those who
are HR positive and received Trastuzumab. HR, Hormone receptor; TRZ, Trastuzumab. Adjusted by age, race/ethnicity, stage at diagnosis, grade
and year of diagnosis.
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with early relapses, 20% of HR-negative patients had the
brain as the first site of recurrence versus 11% of HR-
positive patients; within the subgroup of patients with
late relapses, 18% of patients had the brain as the first
site of recurrence versus 24% of HR-positive patients.
Multiple prior studies have described differences in
the hazard of relapse and death over time according to
HR status [20,38]. We found that HR status is also asso-
ciated with the hazard of death over time within the
HER2-positive population. Patients with HR-/HER2+
tumors faced a higher risk of death within five years of
initial diagnosis; however, beyond five years no statisti-
cally significant differences in hazards of death between
groups were found. Similar results can be observed
when observing the shape of the survival curves in the
adjuvant trials. For example, both in the CALGB9344/
INT0148 and in the HERA trial this difference in the
hazard of relapse over time is apparent [12,15].
Concordant with previous knowledge, trastuzumab
increases the rates of survival independently of HR sta-
tus. After stratifying by adjuvant trastuzumab use, the
differences in survival by HR status persisted. It is worth
noting that despite a lower rate of pathologic complete
responses (pCR) among patients with HR+/HER2+
tumors across neoadjuvant trials [10,39-45], the overall
prognosis of such patients is not worse than those with
HR-/HER2+ tumors. These findings also suggest that in
patients with HR+/HER2+ tumors, lack of pCR will,
potentially, have less prognostic value than among
patients with HR-/HER2+ tumors [46].
Finally, we explored the agreement in ER, PR and
HER2 between primary and metastatic biopsies. Previous
studies showed that discordance rates between primary
and metastatic samples range between 10% and 40%.
Discordance may be associated with: a) methodological
factors, b) intratumoral heterogeneity and c) clonal
selection associated with adjuvant therapy. The relative
contribution of each of these factors is not determined,
although it is believed that a true switch in biology
should be a rare event [47]. We found a 49% rate of any
discordance between primary and metastatic samples,
including a switch from HER2-positive to HER2-nega-
tive in 17% of cases. The influence of neoadjuvant che-
motherapy plus trastuzumab on HER2 has been
investigated, with a loss of HER2 amplification/overex-
pression in 12% to 43% of the cases with residual dis-
ease [48]. Previous studies suggested that discordance
between primary and metastatic samples can have prog-
nostic value [49,50], and further investigation of the bio-
logic, prognostic and predictive value of the discordance
between primary and metastatic samples is warranted.
Our study had a number of strengths. We had access
to a large prospectively collected dataset which drew
from large centers distributed geographically across the
U.S. Because the sample was limited to patients who
initially presented with early stage disease, we could
adjust for clinically relevant tumor- and treatment-
related variables. Unlike the majority of adjuvant trials,
we captured all sites of both first and subsequent recur-
rence, and thus were able to provide a broader picture
of the natural history of HER2-positive disease. In addi-
tion, analysis of metastatic patterns in our study was
less biased than if we had relied on clinical trials in the
metastatic setting, where inclusion/exclusion criteria
could introduce significant selection bias (for example,
restrictions on patients with brain metastases, elevated
liver function tests, and so on). Finally, by only including
patients with metastatic disease who were initially seen
at time of early stage diagnosis, we hoped to minimize
potential referral bias, which is a valid concern given the
nature of the NCCN participating institutions. For
instance, patients referred to an NCCN center for the
first time to consider a third-line chemotherapy trial
would not be included in this dataset.
Our study also had several limitations. HR status was
based on the assessment provided by the breast cancer
pathologists at the time of diagnosis. We did not con-
duct central pathologic review of the tumor samples nor
did we require uniform pre-specified cut-offs for these
markers. The classification was based on the standards
used in each center applicable at the time of diagnosis.
It is likely that academic pathologists at the participating
NCCN institutions reviewed specimens as part of rou-
tine clinical care, which is reassuring as to the quality of
the information provided. However, we acknowledge the
potential for some difference in interpretation over time,
particularly in the setting of low-level (<10%) expression.
Because the study was limited to patients who pre-
sented to NCCN centers, we cannot rule out a potential
referral bias. However, it is unlikely that the impact of
HR in HER2 disease would be different in a population-
based sample, and our data are consistent with other
published data of the impact of HR status in HER2-posi-
tive disease. Patients received a variety of neoadjuvant
and adjuvant therapies and, as expected, the use of tras-
tuzumab increased over time. However, results were not
materially different after adjusting for the use of trastu-
zumab, suggesting that our findings regarding recur-
rence patterns are relevant to current practice.
With respect to our analysis of discordance in HR and
HER2 between primary and metastatic samples, we did
not conduct central pathologic review of the tumor sam-
ples, and cannot rule out technical issues as a cause of dis-
cordance. However, as previously noted, it is likely that
almost all specimens were reviewed as part of routine clin-
ical care at the participating NCCN academic institutions.
Finally, we used classical pathological markers (ER/PR
and HER2) as a proxy for the intrinsic subtypes. For
Vaz-Luis et al. Breast Cancer Research 2012, 14:R129
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practical purposes, it is generally accepted that intrinsic
subtypes are approximated using clinicopathological cri-
teria [7,51]. However, several groups have reported vary-
ing levels of concordance between assignments of
subtype by IHC and gene expression array criteria, and
most suggest that the information provided by the mole-
cular subtypes expands the information provided by
classical clinicopathologic markers. A combined dataset
that included 106 patients that belong to the HER2
enriched subtype, comprised 51% ER-negative/HER2-
positive, 15% ER-positive/HER2-positive and even 34%
HER2-negative analyzed by classical procedures. In a
different report, all patients that belong to HER2-like
molecular subtype were HER2-positive, 46% ER-positive
[7,52]. It is conceivable that using gene expression pro-
filing to classify tumors may have resulted in more dra-
matic differences in the patterns of recurrence and
survival outcomes over time.
Conclusions
Our study supports the classification of HER2 disease as
two different entities distinguished by HR. Further work
to understand the relationship between intrinsic subtype
and outcomes restricted to patients with clinically
HER2-positive disease is warranted. We believe this has
implications in both basic and clinical research. In parti-
cular, we believe that the next generation of HER2-
focused clinical trials should integrate HR status (and/or
intrinsic subtype) in their design, either by designing
distinct treatment protocols for patients with HR
+/HER2+ disease compared to HR-/HER2+ disease, or
by allocating patients within strata defined by HR.
Additional material
Additional file 1: Table S1. Treatment characteristics. Treatment
characteristics at the time of diagnosis and at the time of first recurrence.
Note: HR, Hormone receptor.
Additional file 2: Table S2. Type of first (s) recurrence by HR among
patients with documented recurrence - type of site of first(s)
recurrence date. Type of site of first(s) recurrence (local/regional, distant,
combined) by HR among patients with documented recurrence.
Additional file 3: Table S3. Type of first (s) recurrence by HR among
patients with documented recurrence - type of site diagnosed on
first recurrence(s) date. Type of site of first(s) recurrence (ipsilateral
breast, chest wall/local nodes/regional nodes, contralateral breast, bone,
lung, liver, brain, all other sites) by HR among patients with documented
recurrence. * Analysis based on cohort of 458 patients (208, HR positive;
250, HR negative) with documented recurrence, representing a total of
553 sites of recurrence. Proportion of patients does not add up to 100%
as patients could have more than one site of recurrence.
Additional file 4: Table S4. Type of first (s) recurrences by HR
among patients with documented recurrence - type of first(s)
recurrences in the early recurring subgroup. Type of site of first(s)
recurrence (local/regional, distant, combined) by HR among patients with
documented early recurrence.
Additional file 5: Table S5. Type of first (s) recurrences by HR
among patients with documented recurrence - type of site
diagnosed on first(s) recurrences in the early recurring subgroup.
Type of site of first(s) recurrence (ipsilateral breast, chest wall/local nodes/
regional nodes, contralateral breast, bone, lung, liver, brain, all other sites)
by HR among patients with documented early recurrence.* Analysis
based on cohort of 426 patients (187, HR positive; 239, HR negative) with
documented recurrence, representing a total of 515 sites of recurrence.
Proportion of patients does not add up to 100% as patients could have
more than one site of recurrence
Additional file 6: Table S6. Type of first (s) recurrences by HR
among patients with documented recurrence - type of first(s)
recurrences in the late recurring subgroup. Type of site of first(s)
recurrence (local/regional, distant, combined) by HR among patients with
documented late recurrence.
Additional file 7: Table S7. Type of first (s) recurrences by HR
among patients with documented recurrence - type of site
diagnosed on first(s) recurrences in the late recurring subgroup.
Type of site of first(s) recurrence (ipsilateral breast, chest wall/local nodes/
regional nodes, contralateral breast, bone, lung, liver, brain, all other sites)
by HR among patients with documented late recurrence. *Analysis based
on cohort of 32 patients (21, HR positive; 11, HR negative) with
documented recurrence, representing a total of 38 sites of recurrence.
Proportion of patients does not add up to 100% as patients could have
more than one site of recurrence.
Additional file 8: Table S8. Type of first (s) and subsequent
recurrences by HR among patients with documented recurrence-
type of first(s) and subsequent recurrences. Type of site of first(s) and
subsequent recurrence (local/regional, distant, combined) by HR among
patients with documented recurrence.
Additional file 9: Table S9. Type of first (s) and subsequent
recurrences by HR among patients with documented recurrence-
type of site diagnosed on first(s) and subsequent recurrences. Type
of site of first(s) recurrence (ipsilateral breast, chest wall/local nodes/
regional nodes, contralateral breast, bone, lung, liver, brain, all other sites)
by HR among patients with documented recurrence. *Analysis based on
cohort of 458 patients (208, HR positive; 250, HR negative) with
documented recurrence, representing a total of 1,014 sites of recurrence.
Proportion of patients does not add up to 100% as patients could have
more than one site of recurrence.
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